Since 1952, The Mousetrap captivates audiences with its timeless whodunnit charm while offering boundless opportunities for the future through its enduring cultural and commercial legacy.

Modern Meadow is a pioneering company in sustainable materials, specializing in advanced biofabrication. Their innovative technology enables the production of biofabricated leather and other materials, significantly reducing environmental impact and promoting a more sustainable future.

Kobalt has become a destination for songwriters, artists, publishers, and rights holders. With its unique one global roster, one territory approach, the company represents some of the most iconic and exciting songwriters in the world. Today, the company, on average, represents over 40% of the top 100 songs and albums in the US and the UK.

Launched in 2005 by a local family bakery, the brand developed into the largest organic bread company in North America. In 2015 it was taken over by Flower Foods, a leader in the US baking industry. Dave's Killer Bread pioneered the organic whole-grain bread category with its unique recipes and deep commitment to non-GMO ingredients. The company is also known for its focus on employment opportunities for people who have criminal backgrounds, with one of the founders and namesake to the brand, Dave Dahl, having spent an aggregate of 15 years in jail himself.

Inovalon is a leading provider of cloud-based SaaS solutions empowering data-driven healthcare. The Inovalon tech platform brings together national-scale connectivity, real-time primary source data access, and advanced analytics to enable improved clinical outcomes and economics across the healthcare ecosystem.

Royalty Pharma is collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Its portfolio of royalties entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.